C-erbB-2: expression in patients with breast carcinoma in comparison to patients with benign breast diseases

Anticancer Research

Volumn 16, Issue 2, 1996, Pages 765-772

  Kalogeraki, Alexandra ^a,b   Tzardi, Maria ^a   Datseris, George ^a   Kanavaros, Panagiotis ^a   Karvelas, Costas ^a   Chalkiadakis, George ^a   Tsiftsis, Demitris ^a   Delides, George ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b UNIVERSITY OF CRETE   (Greece)

Author keywords

Atypical fibrocystic disease; Breast carcinoma; C erbB 2; Fibroadenoma; FNA

Indexed keywords

ARTICLE; BREAST CARCINOMA; BREAST FIBROADENOMA; FEMALE; FIBROCYSTIC BREAST DISEASE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE C ERB; PRIORITY JOURNAL;

BREAST NEOPLASMS; FEMALE; FIBROADENOMA; FIBROCYSTIC BREAST DISEASE; HUMANS; RECEPTOR, ERBB-2;

EID: 0029945089     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (74)

1. Adnane J, Gaudray P, Sirnon M-P, Simony-Lafontaine J, Jeanteur P, Theillet C: Proto-oncogene amplification and human breast tumor phenotype Oncogene 4: 1389-1395, 1989.
2. Akiyama T, Sudo C, Ogawava H, Toyoshima K and Yarnamoto T: The product of the human c-erbB-2 gene A185-kilodalton glycoprotein with tyrosine kinase activity Science 232: 1644-1646, 1986.
3. Anderson TJ: C-erbB-2 oncogene in breast cancer: the right target or a decoy? Hum Pathol 23: 971-973, 1992.
4. Bargmann CI, Hung M-C, Weinberg RA: Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 45: 649-657, 1986.
5. Barnes DM, Lammie GA, Millis R, R. Gullick W, J Allen DS, Altman DG: An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma. Br J Cancer 58:448, 1988.
6. Bartkova J, Barnes DM, Millis RR et al: Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ. HumPathol 21: 1164-1167, 1990.
7. Beckmann MW, Niederacher D, Schnurch H-G, Bender HG: Significance of members of the erbB-gene family for tumour development as prognostic factors and novel therapeutic options. Geburtsh Frauenheilk 53: 742-753, 1993.
8. Beckmann MW, Tutschek B, Kruger KH, Niederacher D, Risse BC, Ruppert C, Schnurch HG, Bender HG: Biochemical and immunohistochemical detection of the epidermal growth factor receptor (EGF-R) in breast tumor specimens Int J Oncol 3: 389-397, 1993.
9. Berger MS, Locher GW, Saurer S and 4others. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcicoma with nodal status and nuclear grading. Cancer Res 48: 1238, 1988.
10. Bianchi S, Paglierani M, Zampi G, Gardona G, Cataliatti L, Bonardi R & Ciatto S: Prognostic significance of c-erbB-2 expression in node negative breast cancer: Br J Cancer 67: 625-629, 1993.
11. Borg A, Sigurdsson H, Tandon AK & 4others. Proto-oncogene amplification in human breast cancer. Nordic Cancer Union Symposium Stockholm 1989 (abstract).
12. Borg A, Daldetorp B, Ferno M, Killander D, Olsson H, Sigurdsson H: ERBB2 amplification in breast cancer with high rate of proliferation. Oncogene 6: 137-143, 1991.
13. Cline MJ, Battifora H & Yokota J: Proto-oncogene abnormalities in human breast cancer correlation with anatomic features and clinical course of disease: J Clin Oncol 58: 453, 1987.
14. Corbett IP, Henry JA, Angus B et al: NCL-CBI 1, a new monoclonal antibody recognizing the internal domain of the c-erbB-2 oncogene protein effective for use on formalin-fixed, paraffin-embedded tissue. J Pathol 161: 15-25, 1990.
15. Coussens L, Yang-Feng TL, Liao YC & 9 others: Tyrosine Kinase receptor with extensive homology to EGF receptor shares chromosomal location with new oncogene: Science 230: 1132, 1985.
16. De Potter CR, Beghin C, Makar AP et al: The neu-oncogene protein as a predictive factor for haematogenous metastsses in breast cancer patients. Int J Cancer 45: 55-58, 1990.
17. Fontaine J, Tesseraux M, Klein V et al: Gene amplification and expression of the neu (c-erbB-2) sequence in human mammary carcinoma. Oncology 45: 360-363, 1988.
18. Guerin M, Gabillot M, Mathieu M-C & 4 others: Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance. Int J Cancer 43: 201, 1989.
19. Gulliclc WJ, Love SB, Wright C, Barnes DM, Gusterson B, Harris AL & Altman DG: C-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 63: 434-438, 1991.
20. Gusterson BA, Machin LG, Gullick WJ, et al: Immunohistochemical distribution of c-erbB-2 in infiltrating and in situ breast cancer. Int J Cancer 42: 842-845, 1988.
21. Gusterson BA, Machin LG, Gullick WJ, et al: C-erbB-2 expression in benign and malignant breast disease. Br J Cancer 58: 453-457, 1988.
22. Hams AL, Nicholson S, Sainsbury R, Wright C, Farndon J: Epidermal growth factor receptor and other oncogenes as prognostic markers. Monogr Natl Cancer Inst 11: 181-187, 1992.
23. Houldsworth J, Cordon-Cardo C, Ladanvi M et al: Gene amplification in gastric and esophageal adenocarcinomas. Cancer Res 50: 6417-6422, 1990.
24. Hung M-C, Yan D-H, Zhao XY: Amplification of the proto-neu oncogene facilitates oncogenic activation by a single point mutation. Proc Natl Acad Sci USA 86: 2545-2548, 1989.
25. Hurwitz N, Sawicki M, Samara G, Passaro E: Diagnostic and prognostic molecular markers in cancer. Am I Surg 164: 299-306, 1992.
26. Hynes NE, Gerber HA, Saurer S et al: Overexpression of the c-erbB-2 protein in human breast tumor cell lines J cell. Biochem 39: 167-173, 1989.
27. International (Ludwig) Breast Cancer. Study Group: Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 10: 1049-1056, 1992.
28. Kalogeraki A, Tzardi M, Datseris G, Kanavaros P, Karvelas C, Challciadakis G, Tsiftsis D and G Delides: Proliferating Cell Nuclear Antigen (PCNA) Expression in Patients with Breast Carcinoma in Comparison to Patients with Benign Breast Diseases. In Vivo 8: 1053-1056, 1994.
29. Keatings L, Sinclair J, Wnght C et al: C-erbB-2 oncoprotein expression in mammary and extramammary Paget's disease: an immunohistochemical study. Histopathology 17: 243-247, 1990.
30. Kiang CB, Krauss MH nd Aaronson SA: Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 22: 974-976, 1985.
31. Knyazev PG, Imyanitov EN, Chernitsa OI and Irina F Nikiforova: Loss of heterozygosity at chromosome 17q is associated with HER-2 amplification and lack of nodal involvement in breast cancer. Int J Cancer 53: 11-16, 1993.
32. Kraus MH, Issing W, Miki T, Popescu NC Aaronson SA: Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumours. Proc Natl Acad Sci USA 86: 9193-9197, 1989.
33. Lammie GA, Barnes DM, Millis RR, Gullick WJ: An immunohistochemical study of the presence of c-erbB-2 protein in Paget's disease of the nipple. Histopathology 15: 504-514, 1989.
34. Loaiciga K, Beckmann MW, Niederacher D, Tutscheck B, Engels K, Klockenbush W, Schnurch H-G and H-G Bender: p185/Her2 and pS2 protein overexpression in breast cancer specimens: Improvement for prediction of response to endocrine therapy. Oncology Reports 1: 625-629, 1994.
35. Lodato RF, Maguire HG, Greene MI, Weiner DB, Livolsi VA: Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast. Mod Pathol 3: 449-454, 1990.
36. Lovekin C, Ellis IO, Locker A, Robertson JFR, Bell J, Nicholson R, Gullick WJ, Elston CN & Blamey RW: C-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer 63: 439-443, 1991.
37. Marks JR, Humphrey PA, Wu K, Berry D, Badarenko N, Kerns B-JM and JD, Iglehart. Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer. Ann of Surg 219(4): 332-341, 1994.
38. Marx D, Schauer A, Reichechr et al: C-erbB-2 expression in correlation to other biological parameters of breast cancer. J Cancer Res Clin Oncol 116: 15-20, 1990.
39. Mc Cann AH, Dervan PA, O Regan M, Codd MB, Gullick WJ, Tobin BMJ, Carney DN: Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. Cancer Res 51: 3296-3303, 1991.
40. Naber SP, Tsutsumi Y, Yin S et al: Strategis for the analysis of oncogene overexpression Studies of the neu oncogene in breast carcinoma. Am J Clin Pathol 94: 125-136, 1990.
41. Noguchi M, Koyasaki N, Ohta N, Kitawa H, Earashi M, Thomas M, Miyazalci I, Mizukami Y: C-erbB-2 oncoprotein expression versus internal mammary lymph node metastases as additional prognostic factors in patients with axillary lymph node-positive breast cancer. Cancer 69: 2953-2960, 1992.
42. Noguchi M, Mizukami Y, Kinoshita K, Earashi M, Thomas M, and Miyazaki I: Expression of c-erbB-2 and epidermal growth factor receptor in breast carcinoma: Prognostic value and correlation with clinicopathological and biological variables. Oncol Repts 1: 563-569, 1994.
43. Noguchi M and Miyazaki I: Prognostic factors in breast cancer and their controversies(review)Oncol Repts 1: 1157-1163, 1994.
44. Paik S, Hazan R, Fisher ER et al: Pathologic findings from the National Surgical Adjuvant Breast and Powel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. JClinOncol 8: 103-112, 1990.
45. Parkes HC, Lillycrop K, Howell A et al: C-erbB-2 mRNA expression in human breast tumours. Comparison with c-erbB-2 DNA amplification and correlation with prognosis Br J Cancer 61: 39-45, 1990.
46. Plowman GD, Culouscou JM, Nitney GS, Green JM, Calton GW, Foy L, Neubauer MG, Shoyab M: Ligand-specific activation of HER4/p180 erbB4, a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci USA 90: 1746-1750, 1993.
47. Ramachandra S, Machin L, Ashley S, Monaghon P, Gusterson BA: Immunohistochemical distribution of c-erbB-2 in situ breast carcinoma. A detailed morphological analysis. J Pathol 161: 7-14, 1990.
48. Rio MC, Belloco JP, Gairard B & 7 others: Specific expression of the pS2 gene in subclasses of breast cancers in comparison with expression of their estrogen and progesterone receptors and the oncogene ERBB2. Proc Natl Acad Sci USA 84: 9243, 1987.
49. Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI and Weinberg RA: The neu oncogene an erb-B-related gene encoding a 185000-Mr tumour antigen. Nature 312: 513-516, 1984.
50. Schneider PM, Hung MC, Chiocca SM et al: Differential expression of c-erbB-2 gene in human small cell and non-small cell lung cancer. Cancer Res 49:4968-4971, 1989.
51. Seshadri R, Matthews C, Dobrovic A & Horsfall DJ: The significance of oncogene amplification in primary breast cancer. Int J Cancer 43: 270, 1989.
52. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, MC Guire WJ: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987.
53. Slamon DJ, Godolphin W, Jones LA et al: Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1987.
54. Singleton TP, Niehans GA, Gu F, Litz C, Hagen K, Qiu Q, Kiang D and John G Strickler: Detection of c-erbB-2, activation in paraffin-embedded tissue by immunohistochemistry HumPathol 23: 1141-1150, 1992.
55. Somerville IE, Clarke LA, Biggart JD: C-erbB-2 overexpression and histological type of in situ and invasive breast carcinoma. J Clin Pathol 45: 16-20, 1992.
56. Soomro S ,Shousha S, Taylor P, Shepard HM ,Feldmann M: C-erbB-2 expression in different histological types of invasive bresst carcinoma. J Clin Pathol 44: 211-214, 1991.
57. Tal M, Wetzler M, Josefiberg Z et al: Sporadic amplification of the HER2/neu proto-oncogene in adenocarcinomas of various tissues. Cancer Res 48: 1517-1520, 1988.
58. Tandon AK, Clark GM, Chamness GC, Ullrich A, Mc Guire WL: HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 7: 1120-1128, 1989.
59. Thor AD, Schwartz LH, Koerner FC et al: Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up. Cancer Res 49: 7147-7152, 1989.
60. Tsuda H, Hirohashi S, Shirnosato Y & 11 others. Correlation between long term survival in breast cancer patients and amplification of two putative oncogene-coamplification units hst-1/int-2 and c-erbB-2 lear 1. Cancer Res 49: 3104, 1989.
61. Union Internationale Contre le Cancer: Breast (ICD-0174) in: TMN classification of malignant tumours. Harmer MH (ed). ed 4, Berlin. Springer - Velag pp: 93-99, 1987.
62. Van de Vijver MJ, Peterse JL, Mooi WJ et al: neu-Protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 319: 1239-1245, 1988.
63. Van de Vijver, MJ Peterse JL, Mooi WJ & 4 others: Neu-protein expression in breast cancer. N Engl J Med 319: 1239, 1988.
64. Varley JM, Swallow JE, Brammar WJ, Whitta Ker JL, Walker RA:Alterations to either c-erbB-2 (neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. Oncogene 1: 423-430, 1987.
65. Venter DJ, Tuzi NL, Kumar S and Willian J Cullick: Over-expression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification. Lancet 1: 69-72, 1987.
66. Vogelstein B, Fearon ER, Hamilton SR et al: Genetic alterations during colorectal tumour development. N Engl J Med 319: 525-532, 1988.
67. Walker RA, Senior PV, Jones JL et al: An immunohistochemical and in situ hybridization study of c-myc and c-erbB-2 expression in primary human breast carcinomas J Pathol 158: 97-105, 1989.
68. Walker RA, Gullick WJ, Varley JM: An evaluation of immunoreactivity for c-erbB-2 protein as a marker of poor short-term prognosis in breast cancer. Br J Cancer 60: 426-429, 1989.
69. Wright C, Angus B, Nicholson S & 6 others. Expression of cerbB-2 oncoprotein: a prognostic indicator in breast cancer. Cancer Res 49: 2087, 1989.
70. Yamamoto T, Ikawa S and Akiyama T et al: Similarity of protein encoded by the human c-erbB-2 gene to epidermal growth factor receptor. Nature 319: 230-234, 1986.
71. Yokota J, Yamamoto T, Miyajima N et al: Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue. Oncogene 2: 283-287, 1988.
72. Zeillinger R, Kury F, Czerwenka K & 11 others: HER-2 amplification, steroid receptors and epidermal growth factor receptor in primary breast cancer. Oncogene 4: 109, 1989.
73. Zhou D, Battifora H, Yokota J, Yamamoto T and Cline MJ: Association of multiple copies of the c-erbB-2 oncogene with spread of the breast cancer. Cancer Res 47: 6123, 1987.
74. Zhou D-J, Ahuja H and Cline MJ: Proto-oncogene abnormalities in human breast cancer: c-erbB-2 amplification does not correlate with recurrence of disease. Oncogene 4: 105, 1989.